Compass Wealth Management LLC bought a new position in Quest Diagnostics Incorporated (NYSE: DGX) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 3,564 shares of the medical research company's stock, valued at approximately $679,000. Other institutional investors also

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Quest Diagnostics CEO Jim Davis says the company's Alzheimer's testing through blood work can help disagnons the disease a lot sooner and get patients into specialist earlier.

Consolidated Revenues: $2.81 billion, up 7.1% year-over-year.Organic Revenue Growth: 6.4% in the fourth quarter.Diagnostic Information Services Revenue Growth:

Quest Diagnostics Incorporated (DGX) Q4 2025 Earnings Call Transcript

DGX tops Q4 EPS and revenue estimates as volumes rise, shares jump premarket, and 2026 guidance points to steady growth.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Quest Diagnostics (DGX) came out with quarterly earnings of $2.42 per share, beating the Zacks Consensus Estimate of $2.35 per share. This compares to earnings of $2.23 per share a year ago.

Quest Diagnostics on Tuesday forecast 2026 profit and revenue above Wall Street estimates after beating expectations for fourth-quarter results on strong demand for its diagnostic tests.

Fourth quarter revenues of $2.81 billion, up 7.1% from 2024 Fourth quarter reported diluted earnings per share ("EPS") of $2.18, up 11.8% from 2024; and adjusted diluted EPS of $2.42, up 8.5% from 2024 Full year revenues of $11.04 billion, up 11.8% from 2024 Full year reported diluted EPS of $8.75, up 13.8% from 2024; and adjusted diluted EPS of $9.85, up 10.3% from 2024    Full year cash from operations of $1.89 billion Full year 2026 revenues expected to be between $11.70 billion and $11.82 billion  Full year 2026 reported diluted EPS expected to be between $9.45 and $9.65; and adjusted diluted EPS expected to be between $10.50 and $10.70 SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2025.